---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022603"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:49:42.119063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates

## Summary
- Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
- Granted NIH SBIR award of $500,000 for influenza A/B replication inhibitor program.
- Q3 2025 R&D expenses $954,000 vs $3.2M in Q3 2024; net loss $2.0M ($0.19 per share) vs $4.9M ($0.49 per share) year-over-year.
- Raised $4.7M in registered direct offering in September 2025 and $1.03M in private placement in October 2025.
- CC-42344 Phase 2a study completed; showed favorable safety, no SAEs; efficacy not reported due to trial conduct issues.

## SEC filing metadata
- accession: 0001493152-25-022603
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/0001493152-25-022603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022603
- JSON: https://secwatch.observer/filing/0001493152-25-022603.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.